Feb 23, 2026 by Katie BrockmanBetter Buy: How Small-Cap ETFs ISCG and IJT Compare on Fees, Risk, and IncomeWeighing cost, diversification, and risk, this side-by-side ETF analysis highlights key trade-offs for small-cap growth investors.
Feb 23, 2026 by Katie BrockmanSmall-Cap Showdown: How Vanguard's VB Compares to Schwab's SCHA on Fees, Risk, and DiversificationExplore how key differences in fees, sector focus, and risk profiles set these two small-cap ETFs apart for investors.
Feb 23, 2026 by Rich SmithWhy Novo Nordisk Stock Just CrashedGLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.
Feb 23, 2026 by Rick OrfordDisney's 2026 Film Slate Could Ignite a Powerful ComebackDisney's 2026 movie slate could unlock billions in box office revenue and force Wall Street to rethink the stock. Is now the time to buy before a rerating?
Feb 23, 2026 by Prosper Junior BakinyEli Lilly: The Weight‑Loss and Diabetes Powerhouse I'd Hold Through Any Market CrashThe stock looks unstoppable.
Feb 23, 2026 by Jonathan PoncianoViridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million StakeViridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.
Feb 23, 2026 by Jonathan PoncianoSpyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 MillionSpyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.
Feb 23, 2026 by Justin Pope2 Unstoppable Growth Stocks to Buy Right Now for $1,000These companies just turned in fourth-quarter earnings reports that should have investors salivating at their upside in 2026 and beyond.
Feb 23, 2026 by James HalleyThis 4.9%-Yield Oil Pipeline Stock Is up 18% in 2026 -- and Still Looks CheapThe midstream oil and gas company has scheduled its fourth-quarter earnings on Feb. 23.
Feb 23, 2026 by Jonathan PoncianoBiotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50%Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.
Feb 23, 2026 by Reuben Gregg Brewer3 High-Yield Energy Stocks to Buy in FebruaryWith yields of up to 6%, these three reliable income generators are still attractive buys as February draws to a close.
Feb 23, 2026 by Jonathan PoncianoBiotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.
Feb 23, 2026 by Reuben Gregg BrewerHere's Why I Wouldn't Touch Tilray With a 10‑Foot PoleTilray Brands is expanding its business at a rapid clip, but there are risks associated with this growth effort.
Feb 23, 2026 by David DierkingHow This International ETF Could Complement a U.S.-Heavy PortfolioMany U.S. investors focus solely on the S&P 500 for their portfolio. Adding international stocks makes it built better for the long term.
Feb 23, 2026 by Keithen DruryThe First 3 Stocks I'm Buying if the Market CrashesA stock market crash can occur at any time. Are you ready?
Feb 23, 2026 by Dana GeorgeThe Simple Mistake That Could Sabotage Your 401(k) in 2026There's no reason to allow fees to eat into the money you've worked so hard to save.
Feb 23, 2026 by Matt DiLalloInvesting $3,000 Into These 3 Ultra-High-Yielding Dividend Stocks Could Generate Hundreds of Dollars in Annual Passive IncomeThese companies can turn $3,000 into a lucrative income stream.
Feb 23, 2026 by Rick MunarrizNike, Target, and Home Depot Stocks Just Got a Massive Win From the Supreme Court. Here's What Investors Need to Know.A lot of companies hit hard by tariffs could get back on track under a kinder climate.
Feb 23, 2026 by Reuben Gregg BrewerHere's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is ClearModerna made a fortune with COVID vaccines, but revenue has since declined.
Feb 23, 2026 by Justin PopeThis AI Stock Soared 92% Last Year. Is It Still a Buy for 2026?This new company is riding the AI data center spending spree better than anyone.
